Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.47 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.44 |
| ▸ | MTTP | P55157 | 3/20 | 0.42 |
| ▸ | NPY2R | P49146 | 9/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | APOB | P04114 | 1/20 | 0.39 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800472 | 0.90 | EIF2AK3 (0.49) | SMOEIF2AK3NPY2RCREBBP | |
| SCHEMBL6806265 | 0.89 | EIF2AK3 (0.48) | SMOEIF2AK3MTTPNPY2RCREBBP | |
| SCHEMBL6809001 | 0.88 | EIF2AK3 (0.49) | SMOEIF2AK3MTTPNPY2RCREBBP | |
| SCHEMBL6809248 | 0.87 | SMO (0.56) | SMOEIF2AK3NPY2RCYP11B1CYP11B2 | |
| SCHEMBL6672281 | 0.86 | EIF2AK3 (0.49) | SMOEIF2AK3NPY2RCYP11B1CYP11B2 | |
| SCHEMBL6668503 | 0.86 | EIF2AK3 (0.51) | SMOEIF2AK3CREBBP | |
| SCHEMBL6804490 | 0.85 | EIF2AK3 (0.50) | SMOEIF2AK3MTTPCYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL6664580 | 0.85 | EIF2AK3 (0.50) | SMOEIF2AK3CREBBP | |
| SCHEMBL6667301 | 0.85 | SMO (0.51) | SMOEIF2AK3CYP11B1CYP11B2CREBBP | |
| SCHEMBL6798779 | 0.84 | EIF2AK3 (0.47) | SMOEIF2AK3NPY2RCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1383760-A1 | BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002090347-A1 | AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | SMO 4390/4885EIF2AK3 2638/4885MTTP 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.